PolyPid Announces Presentation of D-PLEX₁₀₀ Phase 2 Clinical Data at ASM Microbe 2022
PolyPid Ltd. (Nasdaq: PYPD) announced that data from its Phase 2 clinical trial of D-PLEX100 for preventing surgical site infections in elective colorectal surgery will be presented at the ASM Microbe 2022 conference on June 9-13, 2022.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
PolyPid Ltd. (Nasdaq: PYPD) announced that data from its Phase 2 clinical trial of D-PLEX100 for preventing surgical site infections in elective colorectal surgery will be presented at the ASM Microbe 2022 conference on June 9-13, 2022. The study evaluates D-PLEX100 alongside standard infection prophylaxis. Dr. Judith Steenbergen will present findings on the impact of the doxycycline-eluting formulation. PolyPid's D-PLEX100 is a lead candidate in Phase 3 trials, targeting soft tissue infections.
Positive
- D-PLEX100 successfully demonstrated efficacy in Phase 2 trials.
- Presentation at ASM Microbe 2022 showcases the company's commitment to addressing surgical site infections.
- D-PLEX100 is advancing to Phase 3 trials, indicating progress toward market readiness.
Negative
- None.
Details
News Market Reaction – PYPD
The recorded move for PYPD in the trading session of this news was -0.56%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Phase 2 clinical data on the efficacy of D-PLEX100 in surgical site infection prevention in elective colorectal surgery will be presented during a poster presentation
PETACH TIKVA, Israel, June 06, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, announced today that data from a previously completed Phase 2 clinical trial of D-PLEX100 will be highlighted in a presentation at the upcoming American Microbiology Society (ASM) Microbe 2022, being held on June 9-13, 2022, in Washington, D.C.
The abstract, ‘Incisional microenvironments and reduction in SSIs in patients treated with a local doxycycline-eluting formulation,’ evaluates the effect of D-PLEX100 in combination with surgical site infection standard of care prophylaxis regimen in elective colorectal surgery. The data will be presented by Judith Steenbergen, Ph.D., President of Scientific and Medical Affairs Consulting (SMAC). The abstract will be available on https://www.polypid.com/ following the presentation.
About PolyPid
PolyPid Ltd. (Nasdaq: PYPD) is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics, PolyPid’s proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients, enabling precise delivery of drugs at optimal release rates over durations ranging from several days to months. PolyPid’s lead product candidate D-PLEX100 is in Phase 3 clinical trials for the prevention of soft tissue abdominal and sternal bone surgical site infections. In addition, the company is currently in preclinical stages to test the efficacy of OncoPLEX for treatment of solid tumors, beginning with glioblastoma. For additional company information, please visit http://www.polypid.com and follow us on Twitter and LinkedIn.
References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. PolyPid is not responsible for the contents of third-party websites.
Corporate Contact:
PolyPid Ltd.
Dikla Czaczkes Akselbrad
EVP & CFO
Tel: +972-747195700
Investor Contact:
Bob Yedid
LifeSci Advisors
646-597-6989
Bob@LifeSciAdvisors.com
Media Contact:
Nechama Feuerstein
FINN Partners
551-444-0784
Nechama.Feuerstein@finnpartners.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.